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Abstract

VOLUMETRIC GROWTH MODEL OF HUMAN MEDULLOBLASTOMA IN THE NUDE
MOUSE CEREBELLUM

By Thomas Sanderson Gavigan, M.S.

A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2010.

Director: William C. Broaddus, M.D. Ph.D.
F. Norton Hord, Jr. Professor
Department of Neurosurgery
Co-Director: Timothy E. Van Meter, Ph.D.
Associate Professor
Department of Neurosurgery

Medulloblastoma is the most common brain tumor in children, accounting
for 10-20% of primary central nervous system (CNS) neoplasms and
approximately 40% of all posterior fossa tumors.

It is a highly invasive

embryonal neuroepithelial tumor that typically arises in the cerebellar vermis and
has a tendency to disseminate throughout the CNS early in its course. The
molecular mechanisms of the disease largely remain uncharacterized, as the
clinical treatment is still associated with mortality and severe side effects.

The
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development of a clinically relevant in vivo model is important not only to further
understand the disease but also to provide a method with which to test novel
therapeutics.

This study quantified the volumetric growth of a human

medulloblastoma (VC312) in the athymic nude mouse cerebellum using Gdenhanced T1-weighed MRI scans. Additionally, a medulloblastoma flank tumor
model was used to explore the in vivo effect of the oral anti-cancer agent that
inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. In the
orthotopic intracerebellar tumor model, perifosine significantly increased the
survival

of

dissemination.

treated

mice

while

qualitatively

reducing

leptomeningeal

In the flank model, perifosine effectively suppressed the

volumetric growth, decreased activation of the AKT pathway and reduced cellular
proliferation in treated mice.

Chapter 1
Introduction

Brain Tumors
The brain tumor is for both patients and physicians one of the most
dramatic forms of human disease. While primary brain tumors only account for
2% of cancer deaths, their occurrence is responsible for 7% of years of life lost
before the age of 70 (Kaye and Laws 1995). An estimated 22,070 new cases of
primary malignant brain and central nervous system tumors were diagnosed in
the United States in 2009 (12,010 in males and 10,060 in females). This
represents approximately 1.5% of all primary malignant cancers diagnosed in the
United States in 2009 (CBTRUS, 2009).
A primary brain tumor is an accumulation of abnormal cells that starts
within the cranial vault.

A brain tumor can arise from the tissue of the brain,

around the brain, nerves, or glands.

Tumors can destroy normal brain cells via

inflammatory response, causing increased intracranial pressure, or by direct cellto-cell contact (Buckner et al., 2007).

Brain tumors are classified by where they

appear in the Central Nervous System (CNS), which includes the brain and spinal
cord, the kind of tissue that is involved, the cellular aggressiveness or grade, and
malignancy (Buckner at el 2007).

The WHO classification is a common
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neoplasm scaling system that was ratified in 1993 to classify each tumor based
on its cell of origin (Kleihues et al 1993).
The difference between normal and neoplastic growth occurs with the
disruption of several crucial elements of central nervous system (CNS)
development.

First, normal cell processes such as modulation of cell

proliferation, differentiation and cell death are altered. Second, the alteration of
the microenvironment in and around the cell changes important regulatory cues.
Thirdly, the combination of these alterations generates a new combination of
signals that have an effect on the cells intrinsic biologic activity, leading to the
abnormal growth (Kaye and Laws 1995).
The

most

medulloblastoma

common
(MB)

malignant

(CBTRUS,

brain

2009),

tumor

a

highly

in

children

invasive

is

the

embryonal

neuroepithelial tumor that arises in the cerebellum and tends to disseminate
throughout the CNS early in its course (MacDonald, 2010). Unfortunately, onethird of MB tumors remain incurable - while multimodality treatment has
improved survival, these interventions nevertheless have several damaging
effects in the long run. Novel therapies include small molecule inhibitors such as
perifosine, which has proven effective in peripheral cancers. Improved tumor
classification will help improve directed treatment.

An improved model of the

tumor will include assessment of molecular profiles of the MB and estimated
growth rates (Gilbertson et al., 2008).

!

"!

Medulloblastoma

Epidemiology: Infratentorial Primitive Neuroectodermal Tumor
The classification of Primitive Neuroectodermal Tumor or PNET was
proposed in 1973 by Hart and Earle.

While this distinction was useful in

developing clinical protocols to treat a range of CNS embryonal tumors,
especially in children, medulloblastomas demonstrate a confounding diversity,
unlike other PNETs. For example, the architectural and cytological features of
the nodular versus desmoplastic medulloblastoma histologic subtypes are unique.
The MB’s separation from other PNETs has evolved across editions of the WHO
(World Health Organization) classification of CNS tumors (1993, 2000, 2007) and
reflects the MB origin and nature. The MB is now recognized as a distinctive
tumor defined by its morphologic and genetic attributes (Gilbertson et al, 2008).
Recent genetic data out of the Arthur and Sonia Labatt Brain Tumour Research
Centre, Toronto, Ontario, Canada further enforces this idea by dividing the tumor
into four distinct molecular subtypes (Northcott et al., 2010).
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By definition the MB arises in the posterior fossa, specifically in the

cerebellum (Rorke et al., 1983). It develops in the vermis and often invades and
occupies the fourth ventricle; further invasion can involve the brain stem
(Halperin et al., 2005).

MB accounts for 13% of childhood primary brain and

CNS tumors (CBTRUS 2010), accounting for approximately 540 diagnosed cases
a year in the US. The peak age of incidence is 7 years and the tumor is more
often seen in boys than girls.

The WHO classifies the medulloblastoma as one

of five embryonal tumors due to its primitive cellular structure, and grade IV
because of its aggressive tendency to metastasize (Kleihues et al., 1993).
Approximately 30% of pediatric patients present with cerebrospinal fluid (CSF)
metastasis (Fouladi et al., 1999).

Clinical and Laboratory Findings
Symptoms
Medulloblastoma patients most commonly present with a three-month
history of headaches, morning vomiting and lethargy. Due to the tumor’s classic
location in the fourth ventricle, patients may experience clumsiness and problems
with simple tasks.

These initial symptoms are secondary to increased

Intracranial Pressure (ICP).

Initial signs of ICP are subtle and difficult to

diagnose. School age children often show decreased academic performance and
personality changes.
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As the tumor increases in size and begins invading the surrounding

cerebellum, the characteristic symptoms appear.

A particularly common

symptom is progressively worsening ataxia mainly in the lower extremities (T.
MacDonald et al., 2009).
diagnose.

For infants, the symptoms are more difficult to

Mainly, infants demonstrate difficulty in gazing upward and appear

to have a forced downward eye deviation, the “setting-sun sign” (R.J. Packer et
al., 1999).
While MB typically disseminates early in the course of the disease, symptoms of
the metastases are not characteristic to patient presentation!(Halperin EC et al.,
(2005).
Diagnosis
Most

patients with medulloblastoma are diagnosed with a CT scan or

MRI. The tumor will appear as a “solid, homogeneous, isodense to hyperdense,
contrast-enhancing, midline cerebellar mass” (Zimmerman et al., 1978).

The

MRI is useful for determining the anatomic origin, extent of the disease and
ruling out cerebellar astrocytoma and ependymoma, which appear similar on the
CT scan (MacDonald et al., 2009).
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Figure 1-1. T1-weighted, Contrast-enhanced MRI of a 4-year-old with
medulloblastoma. Note the enhanced mass within the fourth ventricle. Image
taken from Polkinghorn, Figure 1 (2007).
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Pathology
Found in the cerebellum, the MB is typically a highly cellular, soft, friable
tumor composed of cells with deeply basophilic nuclei of variable size and shape,
sparsely discernible cytoplasm, and abundant mitoses. With the desmoplastic
subtype, the tumors appear lobulated, sharply demarcated and firm, due to
reticulin and collagen deposition, when excised surgically (Rosai et al. 2004).
MBs show a strong tendency to disseminate through the cerebrospinal pathways
and form tumors of variable size along ventricular surfaces, in the subarachnoid
space, or along nerve roots.

They have been found to grow “en plaque”

adjacent to brain or spinal cord (R. Packer et al. 1999).

In various cases,

Homer-Wright Rosettes, which are ring-like accumulations of tumor cell nuclei
around a neuropil-containing or fibrillary core, are present.

Varying levels of

neuronal and glial differentiation are present, suggesting the cell of origin has
the potential for multiple states of differentiation (T. MacDonald et al. 2009).

Molecular biology/ Pathogenesis of Medulloblastomas
Medulloblastoma typically arises in the vermis of the cerebellum during
stages of cerebellar development. The cerebellum is the site of a greater density
of neurons than the cortex and involves complex signaling pathways during
development. A common source of medulloblastoma development is an aberrant
signal from the Sonic Hedgehog (Shh) or Wingless (Wnt) pathway.

These
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signaling molecules are glycoproteins that are secreted from the Purkinje cell
layer (PCL) of the cerebellum during cerebellar evolution.

In normal

development, the Shh or Wnt signal from the Purkinje cells communicates with
the granule cells in the external granular layer (EGL) to differentiate and migrate
through the PCL to the internal granular layer (IGL) where they form neurons. It
has been proposed that medulloblastoma develops when there is an aberrant
Shh or Wnt signal from the Purkinie cells, causing the granule cells to divide
uncontrollably without proper differentiation and migration.

Medulloblastoma is

interesting because the mutations cause variable tumor histology with tumor
cells that range from completely undifferentiated to extensively nodulated and
advanced neuronal differentiation (Fan et al., 2008).

Histology
The medulloblastoma can divided into four different subtypes based on it’s
histology; Classic, Desmoplastic, Anaplastic and Extensive Nodularity. The classic
MB is believed to be Wnt pathway derived and comprises 65% of all diagnoses.
The classic histology shows densely packed cells with hyperchromatic nuclei and
the cells appear to be mostly undifferentiated (Polkinghorn et al. 2007).
Apoptosis is frequent, whereas areas of necrosis are less common (Kleihues et
al. 1997).
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The desmoplastic subtype is associated with a mutated patched-1

(PTCH1) gene and overactive Shh, making up 25% of all MBs (Polkinghorn et al.
2007). The histology shows characteristic pale islands with abundant reticulin
and collagen, reduced cellularity, rarefied fibrillar matrix and increased apoptosis
(Rosai et al. 2004).
The anaplastic or large cell MB shows large, round nuclei with prominent
nucleoli and large areas of necrosis. This subtype shows considerable cytologic
overlap and appears to constitute a unified entity.

Usually high mitotic rates,

typically abundant apoptotic cellular remains may form “confluent lakes and
serpiginous seams” (Rosai et al. 2004).

It has been shown that the anaplastic

subtype incorporates multiple or an accumulation of mutations, with an
association with decreased survival; it makes up only 5% of MBs (Brown HG et
al. 2000).
The extensive nodularity subtype (MBEN) appears to be a variation of the
desmoplastic subtype with extensive nodularity and advanced neuronal
differentiation. This subtype is typified by the linear streaming of rounded,
neuron cell bodies, and tumor cell nuclei within amassed cytoplasmic processes
(Rosai et al 2004). Defined by the WHO as MB with “intranodular nuclear
uniformity on a desmoplastic background” (Giangaspero et al., 2007)., this
subtype is found mostly in infants, is associated with a good prognosis and
makes up 5% of all MBs (Giangaspero F et al., 1999).
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Figure 1-2. Histologic Subtypes of Medulloblastoma. Classic MB with densely
packed, hyperchromatic nuclei.
Cells appear to be undifferentiated (A),
Desmoplastic MB with abundant reticulin and collagen (B), Anaplastic / Large Cell
(LCA) MB with large, round nuclei, prominent nucleoli and large areas of
necrosis(C), and Extensive Nodularity MB with extensive nodules and advanced
neuronal differentiation (D). Images taken from Rosai: Surgical Pathology 9th
Edition (2004).
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Molecular Subtypes

Recent studies performed by Paul Northcott and colleagues at the
University of Toronto Hospital for Sick Children indicate that medulloblastoma
has four distinct molecular subtypes.

Using Affymetrix and SNP genotyping

arrays they identified the following subtypes: WNT, SHH, Group C and Group D.
Each subgroup had a ‘signature’ gene that was over-expressed that was
identified by commercial antibodies. The genes and their associated subgroup
are: DKK1 (WNT), SFRP1 (SHH), NPR3 (Group C) and KCNA1 (Group D)
(Northcott et al. 2010).
Treatment
The

current

treatment

regimen

includes

surgery,

aggressive

chemotherapy, and relatively high doses of craniospinal radiation therapy.
Despite these therapies, 5-year survival is at best 60% to 80%, and moreover,
these therapies affect the developing central nervous system causing memory-,
attention-, motor function-, language-, and visuospatial deficits (Ribi et al. 2005).
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Models of Medulloblastoma
Clinically relevant animal models are needed for the understanding of
tumor biology and testing novel therapies in medulloblastoma. The literature
documents many experimental models of MBs, as described below.
In vitro
In vitro studies are commonplace in research laboratories and allow for
exploration of tumor cell invasiveness and its causative mechanisms.

Ranger et

al, used five distinct MB cell lines in 3-D collagen gel assay to assess tumor
aggressiveness in vitro. While the three dimensional analysis of the MB cell lines
effectively maintains the complex relationships between tumor cells in a 3-D
environment, the model lacks the unique in vivo interactions of the CNS.
Transgenic Mice
Current models of MB transgenic mice have problems with failure to
generate high tumor incidence and variable latency. A current model developed
by Hatton, Villavicencio, Tsuchiya et al.(2008), involves the production of a
Smo/Smo homozygous mouse, in which a constitutively active form of the
Smoothened gene is expressed under a granule neuron precursor (GNP)-specific
promoter.

This medulloblastoma model shows increased tumor incidence,

predictable tumor latency and displayed a leptomeningeal dissemination of MB
cells to the brain and spine.

The model appears to recreate the highly

aggressive and invasive nature of the human disease.

GNPs normally undergo
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massive expansion during CNS development and their proliferation is regulated
by the Shh and Notch signaling pathways. The Shh binds to the PTCH receptor
on GNPs and derepresses the Smoothened receptor, which activates the Shh
target transcription.

The results of this mouse model producing tumors with

multiple features of clinically encountered medulloblastoma suggests that
mutations of this pathway are implicated in the formation of medulloblastoma
(Hatton, Villavicencio, Tsuchiya et al. 2008).

While the transgenic model is a

valuable tool for research, it does not incorporate the various types of mutations
found in human MB tumors. Further, creating transgenic mice is expensive, is
not easily reproducible and does not use human tumor-derived cultured cells.
Therefore, the study of human tumors is impossible with this model.
Knock Out Mice
In knock out mice, an endogenous gene is replaced with a gene that does
not function correctly. The mouse is said to be homozygous or heterozygous
defective depending on whether both or one, respectively, of the homolog genes
are defective. This method of engineering mice can be faulty if the target gene
plays a role in development. This causes the mice to die before birth or shortly
thereafter, which is ineffective for research.

A technique for generating

conditional knockouts has been created to alleviate this problem by turning off a
particular gene after it has played its role in embryogenesis.

The use of

genetically engineered mice are valuable to researchers because they allow the
discovery of which cell signaling pathways play a role in the formation of MB.
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While the signaling pathways activated in a mouse tumor can be similar to those
activated in the human disease, there will be distinct differences between the
human and mouse MB. Therefore, a mouse model of human tumor-derived cells
is still necessary.
Flank Tumor Model
While the cerebellum is the “true” environment of the MB, a flank tumor
model has a faster course, is more easily observable, and more tightly controlled
regarding

tumorigenicity

and

growth

parameters.

Subcutaneous

flank

inoculation of athymic nude mice was chosen for this study in addition to
orthotopic implantation in the cerebellum (see below), because it models a non
permissive growth environment in which tumor cells must appropriately sense
and respond to their surroundings to maintain viability, and provides an efficient
manner of direct tumor growth observation (Pullen, 2010). Therefore, the effect
of therapeutic treatment could be compared against it’s effect in mice following
intra-cerebellar implantation of tumor cells.
Orthotopic Model of Medulloblastoma in Mouse Cerebellum
The orthotopic tumor models present an amount of complexity superior to
classical pathological models. The implantation of tumor cells in their original
tissue allows development of tumor comparable to human tumor with production
of metastasis and interaction of tumor cells with surrounding tissue. This in situ
model can provide a reproducible, reliable and objective method of studying the

!

"#!

effects of therapeutics.

Xiumei Zhao recently established that orthotopic

xenograft mouse models of MB replicated the key histopathological phenotypes
and invasive growth characteristics of the original patient tumors.

This group

showed that serially passed MB cell lines maintain molecular characteristics for at
least three generations, thereby proving that xenograft tumors are molecularly
accurate (Zhao et al. 2010). This further demonstrates the necessity of
developing a clinically relevant model of the medulloblastoma to examine new
therapies that can decrease debilitating therapeutic side effects and treatment
failures that plague patients of MB.
We designed experiments using this information with the intent of
creating a molecularly accurate, human tumor-derived medulloblastoma model,
studying the growth of the disease in the cerebellum, and defining a growth
curve for MB to enable evaluation of potential new therapeutics for treatment of
the disease.
Therapeutics
Perifosine
AKT, also known as Protein Kinase B, is a regulator of cellular survival
pathways aberrantly active in many human cancers including MB, contributing to
cellular growth, proliferation and survival (Gills and Dennis, 2009).

These

characteristics also make AKT an attractive target in cancer therapy and many
inhibitors of AKT are being developed. Perifosine is an oral AKT inhibitor
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currently being tested in phase 2 clinical trials in peripheral cancers. It is an
alkyl-phospholipid, small molecule inhibitor that acts as a competitive inhibitor of
AKT-kinases. The in vitro effects of the drug have been studied extensively in our
lab by Anil Kumar (Kumar et al., 2009). It was found that Perifosine treatment in
vitro led to the rapid induction of cell death in MB cell lines, with marked
suppression of phosphorylated AKT in time- and concentration-dependent
manners (Kumar et al. 2009).

The in vitro studies performed in our lab in

combination with the proven effectiveness of perifosine in peripheral cancers
made it an ideal candidate for this study.
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Chapter 2
Hypothesis and Specific Aims
Rationale: Thorough examination of many models of medulloblastoma has not
shown that an existing model can easily reproduce a human tumor-derived
othrotopic model of the disease. Tumor volumes provide an objective method of
studying the tumor growth and effects of therapeutic agents. The debilitating
side effects and treatment failures demand new/improved therapies.

We

attempted to create a medulloblastoma model in the nude mouse cerebellum
that mimics the molecular fidelity, subtype and histology of the human derived
tumor. Further, we compared this model to Perifosine-treated mice.

Hypothesis I: Human cultured medulloblastoma tumor cells can be induced to
grow in the cerebellum of athymic nude mice to create an orthotopic model.
Specific Aims:
1. Establish effective delivery and placement of tumor inoculum
into the cerebellum.
2. Establish a xenograft tumor line with a highly reproducible
growth pattern in vivo.
3. Determine

the

histologic

and

molecular

medulloblastoma grown in the cerebellum.

subtype

of
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Hypothesis II: Tumor volume can be measured accurately using MRI to
determine the volumetric growth of the medulloblastoma.
Specific Aims:
1. Objectively determine the volume of the tumor from MRI scan
data.
2. Determination

of

in

vivo

growth

pattern

of

primary

medulloblastoma in mouse cerebellum.
Hypothesis III: Orthotopic model can be used to demonstrate the effectiveness
of therapeutics in an in situ model.
Specific Aim:
1. Validate the effective suppression of target signaling molecules
and volumetric growth in vivo after Perifosine treatment.
!
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Chapter 3
Methods

All animal experiments were approved by the Committee for the Care and
Use of Laboratory Animals at Virginia Commonwealth University.

Female

athymic nude Fox n1 mice (Harlan, Indianapolis, Indiana) with an average
weight of 18 to 22 grams were used for all infusions of medulloblastoma cells.
Stereotactic Infusion
Female athymic nude mice were anesthetized by inhalation administration of 0.3
µL/min isoflurane and maintained in an anesthetized state with 0.2 µL/min
isoflurane during the surgery.

Lubricating veterinary ointment was applied to

the eyes and the animal was placed on a heating pad in a stereotactic frame. A
1 cm midline incision was made at the scalp, centered approximately at lambda.
An infusion burr hole was stereotactically created 1.5 mm posterior, 3.0 mm
lateral to lambda using a fine drill bit for all infusions.

A 22s-gauge neede

attached to a 25 µL Hamilton syringe driven by a syringe pump (Bioanalytical
Systems, West Lafayette, Indiana) was lowered 3.5 mm below the surface of the
skull for cerebellar infusions and remained in the cerebellum parenchyma for 5
minutes before the infusion. Five minutes after the infusion, the infusion needle
was slowly raised 1 mm every minute until out of the cerebellum. The burr holes
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were sealed with sterile bone wax.

The incision was then closed with Surgi-lock

2oc (Meridian Animal Health, Omaha, Nebraska), averaging 2 drops along the
length of the incision and held together for 20 seconds. The mouse was placed
under a heat source and monitored until alert and mobile.
water

containing

acetaminophen

(1.6mg/mL)

Mice had access to

(McNeill-PPC,

Inc,

Fort

Washington, PA) for three days following initial dose of buprenorphine (0.05.1mg/kg, S.C.) immediately following tumor cell infusions for pain alleviation
during anesthetic recovery.

The recovery method is important due to the

severely impaired immune systems of these mice.
Six µL of 60,000-cells/ µL in plain DMEM (Invitrogen, Carlsbad, CA) was
infused into the right cerebellum at a flow rate of 0.25 µL/min for 24 minutes.
Cell implants were permitted to grow for 1 week before MRI scanning to confirm
tumor formation. Tumor growth was assessed again at 14 and 21 days via MRI
T1-weighted imaging, DWI and water mapping techniques.

Twenty-one days

post-implantation was chosen as a humane endpoint to reduce prolongation of
potential distress in the animals, since it is a time-point prior to when subject
mortality would be expected (28-30 days). Animals were monitored daily for
signs of pain and distress and if discovered, the animals were euthanized.
Cerebella were collected and sent to the Department of Anatomic Pathology at
Virginia Commonwealth University, Richmond, Virginia.

Cerebellum gross

sections containing intact tumor were then sectioned and subjected to
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neuropathological analysis to determine volume of tumor and extent of tumor
cell infiltration of normal cerebellar tissue.
Subcutaneous Flank Tumor Inoculation
Animals receiving flank inoculations were not anesthetized.

Cell suspensions

were prepared in culture medium free of additives. Target area for inoculation
was the back, midline, with needle angled in the posterior direction of the
mouse.

The target area was prepared with an isopropyl swab.

A maximum of

200 µL total suspension (1,000,000 to 4,000,000 cells) were injected via a 28ga
needle after tenting the cutaneous layer.

The needle was allowed to remain in

place for several seconds after injection to reduce inoculate backflow. A sterile
cotton swab was applied in the target area to reduce potential bleeding.

Flank

inoculation with medulloblastoma cells is expected to produce palpable tumors
within 6-8 days. Tumor volume was assessed at least twice a week afterward.
Tumor volume was not allowed to exceed 2.5cm^3 or 10% of subject body
mass. Mice bearing flank tumors were observed daily for ulceration and necrosis.
If noted, the mice were euthanized.
Magnetic Resonance Imaging
Each mouse to be scanned was anesthetized by intraperitoneal
administration of 100mg/kg Ketamine + 10mg/kg Xylazine (1 : 4).

Lubricating

veterinary ointment was applied to the eyes and the animal was placed under a
heating source.

Gd-DTPa was injected I.V. via tail vein for MRI to monitor
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tumor growth.

Each mouse was placed in an acrylic imaging tube, secured via

plastic ear bars, and fitted with a surface coil. Images were acquired with a 2.4
T, 40-cm bore magnet (Bruker Medical, Inc., Billerica, MA) equipped with a 12
cm inner-diameter, actively shielded gradient insert
strength: 25 G/cm).

(maximum gradient

An actively decoupled RF coil set was used for RF

excitation/reception and was comprised of a 7 cm inner-diameter “birdcage”
design resonator and a 2 cm diameter circular surface coil.
T1 images
A two-dimensional T1 imaging series was generated with a spin echo,
echo-planar imaging sequence preceded by an inversion recovery preparation
period using a hyperbolic secant inversion pulse.

Data was obtained on 3

coronal sections are 20 mm square and at a thickness of 2.5 mm. Inversion
recovery times were: 30, 60, 150, 300, 700, 1300, and 2500 msec.
Derivation of Human Derived Tumor Cells
Human Medulloblastoma xenograft derived from a tumor of a 4-year old
male patient. Established under approved research protocols, and characterized
in our laboratory (Pediatric Neuro-Oncology Laboratory, Virginia Commonwealth
University). Samples of tumor were first obtained to allow full neuropathologic
evaluation and diagnosis, as required for clinical management of the patient’s
disease. The site of origin of all tumor samples was cerebellum. Cells were
grown in DMEM supplemented with 10% heat-inactivated fetal bovine serum,
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glutamine, and 1% penicillin-streptomycin solution at 37*C temperature with 5%
CO2 in a humidified incubator.

All tissue culture reagents and supplements

were obtained from Gibco BRL (Grand Island, NY) unless otherwise noted.
Monolayers of tumor cells were typsinized, counted on a hemacytometer and
viability was assessed by trypan blue exclusion.

Cells were washed twice in

phosphate buffered saline (PBS) and concentration was adjusted appropriately
(Graf et al. 2005).
Determination of Tumor Volume from MRI
The three-dimensional volume of a tumor determined from a twodimensional MRI scan uses the equation for the volume of a spheroid. In this
equation, the volume is equal to four times the radius cubed, all divided by
three. Replacing the radius with the diameter divided by two, and making the
diameter cubed equal to the width of the tumor times the height of the tumor
times the width of the MRI slice, gives a simplified equation for volume. The
volume of a spheroid can be estimated as the width of the tumor times the
height of the tumor times the slice width, all divided by two (!/6 being
approximately !).
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Quantification of VC312 mRNA levels
Total RNA was isolated from VC312 tumor tissue using TRIzol reagent,
using the manufacturer’s protocol (Invitrogen, CA) and standard extraction
protocol (Sambrook and Russell, 2001).

To prepare tissue extracts for RNA

isolation, flash frozen pieces were ground to a fine powder with a frozen mortar
and pestle prior to being added to TRIzol reagent. RNA was quantified using
spectrophotometry to assess concentration of the RNA in the extracts and
treated with RQ1 DNase (Promega, Madison, WI) using the manufacturer’s
protocol.
Western blot analysis for phosphorylated and total AKT
Cultured adherent cells in T-75 flasks were washed with PBS and
incubated with 1 ml of ice-cold RIPA lysis buffer (50 mM Tris-HCl, 150 NaCl,
0.5% SDS, 1% sodium deoxycholate, 1% Nonidet p-40) for 5 minutes on ice
with gentle agitation. Cells were scraped from flasks, sheared with 26.5 gauge
needle and centrifuged at 16000 rpm for 30 minutes at 4°C.
collected and stored at -80°C until use.

Supernatant was

Alternatively, frozen tumor tissue

samples from primary medulloblastoma samples were thawed and suspended in
800 !L ice-cold RIPA buffer containing protease inhibitor cocktail (Calbiochem,
San Diego, CA) and mechanically homogenized. The homogenized tissue was
incubated at 4°C for 15 minutes and centrifuged at 16000 rpm for 30 minutes at
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4°C.
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Protein supernatants were aliquoted and stored at -80°C until use.

Proteins were quantified using the Lowry method and BioRad DC reagent
(BioRad, Hercules, CA) using the manufacturer’s protocol.

A BSA (Pierce,

Rockland, IL) standard curve was used (25!g/ml to 2000!g/ml range).

Equal

amounts of protein were loaded onto Bis-Tris 4-12% density gradient gels
(Invitrogen, Carlsbad, CA) for SDS-PAGE at 120 V using the manufacturer’s
power source and protocol (Novex).

Proteins were transferred (1 hour at 30V)

onto nitrocellulose (Invitrogen) and incubated with 15 ml blocking buffer [5%
bovine milk in Tris-buffered saline (50 mM Tris, pH 7.6, 150 NaCl) plus 0.05%
Tween-20] for 1 hour at room temperature with gentle agitation.

Primary

antibody [anti-Phospho-AKT (1:2000), Pan-AKT (1:2000) and anti-beta-actin
(1:2000)] were added to 10 ml blocking buffer and incubated overnight at 4°C
with gentle agitation. Membranes were washed with rinse buffer [Tris buffered
saline (50 mM Tris, pH 7.6, 150 NaCl) plus 0.05% Tween-20] for 6 x 5 minutes
with vigorous agitation.

HRR-conjugated secondary antibody was added to 10

ml blocking buffer (1:3000, ) and incubated for 1 hour at room temperature with
gentle agitation.
enhanced

Membranes were washed as before and developed using

chemiluminescence

(ECL)

reagents

Piscataway, NJ) and the manufacturer’s protocol.

(Amersham

Biosciences,

Immunoreactivity was

visualized by exposure to autoradiography film (Marsh) and was developed using
an X-OMAT developer (Kodak, Rochester, NY). For quantitative analysis, optical
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densities of autoradiographic bands were measured using ImageQuantTM
software (Amersham Biosciences, Piscataway, NJ).
Determination of Tumor Volume from Caliper measurements
The volume of subcutaneous tumor volumes is an important tool in
assessing disease growth and effectiveness of therapeutics. Manual calipers are
used as a noninvasive technique for measuring tumor volume.

The 2 longest

perpendicular axes of each xenograft tumor were measured to the nearest 0.1
mm by an investigator familiar with collecting caliper measurements of xenograft
tumors in mice. The depth was assumed to be equivalent to the shortest of the
perpendicular axes, defined as y (Tomayko et al, 1989; Euhus et al, 1986).
Xenograft Tumor Volume = xy2 / 2.
In Vivo Analysis of Effects of Perifosine on VC312 Tumor Growth
Groups of mice were inoculated with VC312 tumor cells as described
previously.

When the mice reached post-inoculation day 15 with measurable

tumors, perifosine-containing (36 mg/kg/d) or placebo drinking water was
refreshed every 48 hours for up to 20 days by (n = 4 mice per group). An
amount of 15 mg of Perifosine was weighed and dissolved in 100 mL of sterile
water.

Average daily water consumption was 5 ml per day, resulting in an

average daily dose of 36 mg/kg/d or 252 mg/kg/wk.

The dimensions of the

resulting tumors were determined at least three times per week using a digital
caliper, and the tumor volume (cubic millimeter) was calculated as described
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above. The mice were sacrificed by asphyxiation with regulated CO2, and the
tumors were excised, snap frozen in liquid nitrogen then transferred to a freezer
at –80°C, until use. Protein extracts from the tumors were used to assess the
phosphorylation status of AKT. To determine the effect of perifosine on survival,
we counted the days from the date the treatment (perifosine or control) was
begun to the time the control cohort of mice were sacrificed or to the end of the
perifosine treatment or until euthanasia, as described previously (Zhijie et al,
2010).
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Chapter 4
Results

Creation of Intracerebellar Medulloblastoma Murine Model

The Medulloblastoma cell line VC312 was derived from a tumor of a 4year-old male patient. The primary culture (VC312) of MB was derived from a
tumor of a 2-year old male patient treated at the Virginia Commonwealth
University Health System’s Medical College of Virginia Hospital under an IRB
approved protocol. Briefly, samples of the tumor were first obtained to allow full
neuropathologic evaluation and diagnosis, as required for the clinical
management of the patient’s disease. The sterile dissection of tumor biopsy was
dissociated and plated in 6-well tissue culture plates and expanded in DMEM/F12
medium supplemented with 1% N-2 supplement (Invitrogen), 5% FBS, 20 ng/ml
recombinant human EGF and 10 ng/ml recombinant human bFGF (Beckton
Dickenson). VC312 cells were subsequently maintained in DMEM (with Lglutamine) supplemented with 10% FBS.

Volume of Tumor Injection
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The proper volume of inoculum had to be determined in order to induce

reliable tumor formation within a relatively brief time course, but without
undesirable adverse effects on the recipient animals. It was decided that roughly
10% of the total cerebellar volume would be an acceptable maximum initial
tumor cell infusion, so as to avoid adverse effects of the relatively rapid infusion
process. Thus, based upon the average athymic nude female mouse cerebellum
volume being approximately 60 $L (Airey et al. 2001), we concluded that 6 $L
would be the volume of the tumor inoculum. The tumor cell concentration for
the inoculum was determined from previous experiments performed in our lab as
being a maximum concentration without blocking the fine needle of the Hamilton
syringe (Nottingham 2008). This concentration is equal to 50,000 cells per $L,
which amounts to 300,000 VC312 cells per injection.
Establishment of tumor inoculum into cerebellum
Our lab has completed orthotopic cancer experiments in the past but
never in the cerebellum. Therefore, proper stereotactic coordinates using the
athymic mouse skull sutures had to be established. Using the Mouse Brain Atlas
(mbl.org)(Figure 4-1) it was determined that 1.5 mm posterior from Lambda,
3.0mm lateral and 3.0 mm deep would place the inoculum in the right
hemisphere of the posterior lobe of the cerebellum.
The growth of VC312 xenograft tumor in the cerebellum was confirmed
with MRI (Figure 4-2) and dissection of the mouse brain. Once the growth of
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the human tumor-derived cell line was confirmed, the development of an in vivo
growth pattern for a primary medulloblastoma in the mouse cerebellum could
begin.
Hematoxylin and Eosin Staining
Hematoxylin and Eosin (H&E) stains were performed on representative
formalin-fixed, paraffin embedded tissue sections from representative animals
from all stereotactic infusion parameters by the VCU Anatomic Pathology
Research Services.
Tumor Bearing Mice
Consistent results were observed among all tumor-bearing mice, and as
with the stereotactic infusions, the region of interest was the right cerebellum.
On MRI (Figure 4-2), Gd-enhanced T1-weighted imaging qualitatively
showed tumor enhancement in the cerebellum and around the brain stem.
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Figure 4-1. Scaled Image from Mouse Brain Atlas. Image illustrates the location
of Lambda (lj) as the intersection of the sagittal and lambdoid sutures. The burr
hole was positioned: 1.5 mm anterior, 2.5 mm lateral to lambda, and the
inoculum was positioned 3.0 mm ventral to the burr hole placement. placing the
VC312 cells in the lateral portion of the cerebellum.
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Figure 4-2. Gd-enhanced T1-weighted MRI of an animal on Day 17 Post
Implantation. The image demonstrates a coronal slice from the mouse
cerebellum. The tumor boundary is visible as hyper-intensity seen in the lateral
aspect of the cerebellum.
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The tumor growth in the intracerebellar model was measured using a

formula for the volume of a spheroid (described in the Methods section) at 7
days, 14 days, 21 days and 28 days post-implantation. The average growth of
the MB in the nude mouse cerebellum can be seen in Figure 4-3.
Consistent results were observed in the flank tumor bearing mice, the
region of interest was the flank region and the subcutaneous growth of the
tumor (Figure 4-4). The dimensions of the tumors were measured using a
caliper every third day.

Histology of Tumor
The representative histological images of the in vivo tumors can be seen
in figure 4-5. The tumor is very cellular, with many mitoses and little
cytoplasm. The cells appear to form clusters and rosettes.

!
Figure 4-3. Volumetric Growth of Murine Intracerebellar MB.

"#!

!

"#!

!

"#!
Figure 4-4. Image of a subcutaneous VC312 flank tumor.
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Figure 4-5. Histology of Intracerebellar and Flank VC312 Tumors.
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The Effect of Perifosine on Medulloblastoma cells in vitro

Previous work by Dr. Anil Kumar in this laboratory studied the effect of the
therapeutic agent Perifosone on different MB cell lines in vitro (Kumar et al.,
2009).

His data showed that endogenous active AKT is present at high levels

compared with normal brain samples in MB and derivative cell lines. Treatment
of the MB with perifosine decreases the active AKT levels in a dose-dependent
and time-dependent manner. He also showed that perifosine treatment led to
rapid decreases in cell survival in tumor cells.

Dr. Kumar also reported that

exposure to etoposide and radiation followed with perifosine resulted in greater
thant additive effect on cell death. These results indicate that perifosine, either
alone or in combination with other drugs, might be an effective therapeutic
agent for the treatment of MB. These results highlight the potential value of
studying of the effects of Perifosine in an in vivo model.

The Effect of Perifosine on Medulloblastoma in vivo
Treatment of tumor bearing mice resulted in a decrease of overall tumor
volume in both intracerebellar and flank models. The intracerebellar-implanted
mice were given perifosine treatment beginning sixteen days post-implantation.
The volumetric growth of the intracerebellar implanted MB appears sporadic
initially (Figure 4-6A). However, the effect of perifosine begins to appear when
the tumor volumes are separated into treated and untreated groups and their
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volumes are averaged (Figure 4-6B). Finally, when the tumor volumes are
normalized to the size of the tumor upon initial inspection with MRI (day 7), the
effect of perifosine within the treatment group was significant (figure 4-7).
The effect of perifosine on the growth of the flank tumor model is
illustrated in Figure 4-8. The tumor sizes were normalized to the size of the
tumor at the beginning of treatment and averaged. The effect of perifosine is
significant from eight days post-treatment until the end of the study.
The intracerebellar-implanted mice were given perifosine treatment
following the MRI at day 14. At day 35 post implantation only the four mice
treated with perifosine remained alive. Using a Fisher’s exact test to evaluate
the significance, the effect of perifosine on the survival of intracerebellarimplanted mice is significant (Table 4-1).
The effect of perifosine on the signaling pathways of MB is illustrated in
figure 4-9 by the suppression of active AKT in treated versus untreated MB flank
tumors. Qualitative effects of perifosine on the histology of the tumor are
illustrated in the decreased density of stained cells. Further, when the tumors
were stained with Ki-67, a cellular marker for proliferation, the Ki-67 sections
showed qualitative differences between the treated and untreated tumors. The
treated tumor sections displayed a lower density of Ki—67 positive cells than the
untreated tumor sections. Therefore, perifosine effectively suppressed the
proliferation of MB cells in the treated animal model.
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Figure 4-6. Effect of Perifosine on Growth of Murine Intracerebellar
Medulloblastoma. A. The volumetric growth data for each intracerebellarimplanted mouse are plotted individually. B. The average volumetric growth rates
for perifosine-treated vs untreated mice are demonstrated.
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Figure 4-7. The Effect of Perifosine on the growth of murine intracerebellar
medulloblastoma. Treatment with perifosine began on day 17 post-implantation.
Tumor volumes have been normalized to the volume of the tumor at initial MRI
inspection on day 7 post implantation.
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Figure 4-8. Effect of Perifosine Treatment on Growth of Medulloblastoma Flank
Tumors. Tumor volumes have been normalized to the volume of the tumor at
the beginning of treatment.
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Table 4-1.
Effect of Perifosine on Survival of Mice with intracerebellar
implantation of Medulloblastoma.
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Figure 4-9. Suppression of active AKT by perifosine in VC312 flank tumors. Flank
tumor-bearing mice were treated with perifosine for 20 days and the cell lysates
were
then
subjected
to
Western
blot
analysis.
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Figure 4-10. The effect of perifosine on the histology of medulloblastoma in a
flank tumor model. A. Hematoxylin and eosin staining of treated and untreated
tumor sections. B. Flank tumor sections stained for Ki-67, a marker for cellular
proliferation.
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Chapter 5
Discussion

The medulloblastoma is the most common malignant pediatric brain
tumor, and is still associated with mortality and severe side effects from clinical
treatment (Packer et al., 2003). The development of a clinically relevant in vivo
model is important not only to further understand the disease but also to provide
a new and improved means with which to test novel therapeutics. The standard

in vitro experimental models of human cancer cell lines do not accurately
replicate the conditions, three-dimensional interaction or microenvironment that
a tumor experiences in vivo and orthotopically.
Current models of replicating MB include genetically engineered animal
models (Hatton et al., 2008) and orthotopic xenograft models (Kessler et al.,
2009). These models fail to use a human tumor cell line, which reduces their
usefulness for studying therapies designed for humans.

Further, the clinical

effectiveness of novel therapeutic strategies can more accurately be predicted
when human tumor-derived cell lines are used in an orthotopic xenograft model
(Hoffman et al., 1999).
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Previous intracerebellar xenograft models have been established in SCID

mice, systematically developed and broadly characterized for multiple established
MB cell lines (Qin et al., 2006) excluding VC312. However, these models have
the serious limitation of using established cell lines that have a homogeneous cell
population, uniform growth rate and hypersensitivity to therapy (Qin et al.,
2008).

The development and volumetric characterization using MRI of an

orthotopically implanted primary human MB tumor has not been reported.
In this study, we described the establishment of an intracerebellar model
in athymic nude mice with cells cultured from a primary human tumor.

Utilizing

MRI and a flank tumor model to establish the volumetric growth of the tumor in

vivo we evaluated the preclinical effectiveness of the anti-AKT activities of
perifosine, an established anti-cancer drug that has been taken to phase II
clinical trials for peripheral cancers (Gills and Dennis, 2009).

Our lab had

previously studied the in vitro effects of perifosine and showed that it possessed
potent suppression of AKT signaling activity by decreasing cancer cell survival
and growth (Kumar, et al., 2009). The literature documents that the
phosphatidylinositol 3!-kinase (PI3K)–mediated AKT signaling pathway has been
found to have a role in tumor proliferation and survival (Vivanco et al., 2002),
making the AKT signaling pathway a valuable target for anti-tumor therapeutics.
Further, elevated activation of PI3K/AKT signaling pathways has been found in
MB (Hartmann et al., 2006).
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Repeated MRI scans illustrated volumetric growth and histopathological

features similar to the primary tumor which confirmed successful establishment
of an intracerebellar MB model in nude mice. Using this model, we showed the
effect of perifosine on suppressing tumor growth both in the orthotopic
intracerebellar model and in the flank model.

Perifosine also effectively

increased survival of mice bearing intracerebellar tumors.

Further, perifosine

effectively suppressed active AKT signaling and reduced the density of
proliferating cells in vivo.
An advantage of xenograft models is that the relative tumor growth
dynamics can roughly be predicted by the concentration of tumor cells implanted
(Lampson et al., 2001). Therefore, identical cell concentrations implanted in the
same stereotactic position in the cerebellum would theoretically grow at the
same rate. A further advantage of such a xenograft model would be to allow
objective measurement of the effectiveness of chemotherapy or other
therapeutic strategies. Unfortunately, we found there to be a large variation in
the volumetric growth rates at days 14 and 21 post implantation.

However, by

the end of the study, the sizes of the tumors measured from the MRI scans were
approximately similar, while the overall rates of growth of individual tumors
showed variability.
While faithful reproduction of intracerebellar MB tumors was not
confirmed with histology, leptomeningeal dissemination was evident in both the
MRI scans and the prepared histology.

It should be noted that this corresponds

!

"#!

to a troubling clinical characteristic of MB in humans, with dissemination early in
its course. The murine model of intracerebellar MB established in this study thus
appears to replicate dissemination in the CNS, especially around the brainstem.
This may be a valuable model for novel therapeutic strategies targeting
leptomeningeal dissemination of MB.

It is notable in this regard that despite

prominent leptomeningeal dissemination in these animals, the group receiving
perifosine had a significantly longer survival. This provides significant hope that
this therapeutic strategy could be effective against MB even in patients who have
developed leptomeningeal spread of their tumor.
Limitations of our model included the culturing of the primary tumor prior
to implantation. While the cell cultures of the MB used in the study were limited
to less than five passages, the in vitro culturing could have had an effect on the
heterogeneity of the cell population.

The homogeneous cell population would

make for uniform growth and the possibility of sensitivity to therapy (Kamb et
al., 2005).

A solution to this problem would be the implantation of freshly

resected tumor pieces intracerebellarly, however due to the availability of the
resected samples, cultured primary tumor cells were the best option. Another
issue that should be addressed is the location of the tumor implantation.

The

majority of MBs grow from the vermis of the cerebellum, the site of massive
cellular differentiation during development.

The implantation was positioned in

the right hemisphere of the lateral lobe of the cerebellum because it was the
only feasible target in the cerebellum. Due to the size of the cerebellum in these
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animals, it was far too difficult to position the implantation in the vermis.
Further, the mice used in the study were young adults (4-6 weeks) whose
cerebellar

development

was

mostly

complete,

potentially

reducing

the

microenvironment difference between vermis and lateral hemisphere.
Future studies with this model approach would be appropriate to address
a number of issues highlighted by this work, to improve and extend the
important findings here. In particular the stereotactic refinement, tumor
reproducibility and perifosine dose optimization. Refining the stereotactic
coordinates would improve the reproducibility of the model in the cerebellum.
Proper tumor implantation is the keystone of this model, continuing to optimize
the surgical protocol will allow extension of this model to explore signaling,
angiogenesis and dissemination of the disease. Further, faithful orthotopic
implantation and growth of the primary human MB in the cerebellum allows the
further characterizing of the complexities of this tumor; it will also permit
refinement of the perifosine growth suppression mechanism in vivo.
In order to improve reproducibility; the size and age of mice used in the
model need to be standardized. The volume of the cerebellum varies with each
subject and therefore proper implantation location can fluctuate. Correlating the
stereotactic coordinates to the size and age of the animal should improve the
accuracy of the implantation and the model’s orthotopic fidelity.
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Maximum anti-tumor effect while maintaining increased survival benefits is

the goal of perifosine dose optimization. Exploring the time dependence of
perifosine effectiveness is a logical extension of the therapeutic enhancement.
Further, characterizing the suppression of subarachnoid growth will improve the
understanding of the survival benefits of perifosine.
Finally, optimization of the intracerebellar MB model will allow utilization of the
approaches learned in this work to be applied to newly obtained primary tumor
samples of MB.
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